Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 9: 1142 - 1146

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.09.002

Neonatal surgery topics

Factors related to prognosis of portoenterostomy for type Ⅲ biliary atresia

  • Geng-feng JI ,
  • Zhi-bo ZHANG
Expand
  • Department of Pediatric Surgery, Shengjing Hospital of China Medical University, Shenyang 110003, China
ZHANG Zhi-bo, E-mail: zhangzb@sj-hospital.org.

Received date: 2021-03-15

  Online published: 2021-08-24

Supported by

National Natural Science Foundation of China(81270437);Key R&D Project of Science and Technology Department of Liaoning Province(2017225014)

Fold

Abstract

Objective

·To explore the factors related to the jaundice clearance and native liver survival after portoenterostomy (Kasai's operation) in the children with type Ⅲ biliary atresia.

Methods

·The clinical data of the patients diagnosed as having type Ⅲ biliary atresia, who underwent Kasai's operation in Shengjing Hospital of China Medical University from January 2012 to January 2018, were analyzed retrospectively. According to the prognosis, the children were divided into jaundice clearance group (JC group, which was divided further into early and late JC group) and jaundice non-clearing group (JOC group), or native liver survival group and non-native liver survival group (liver transplantation/death). T/U test, χ2 test, Kaplan-Meier survival analysis, and multivariate Cox regression analysis were employed to analyze the prognostic factors.

Results

·A total of 96 patients were enrolled in this study, including 48 males and 48 females. The average age of operation was (62.1±18.9) d, and the average follow-up time was (16.2±20.3) months. Direct bilirubin decreased to normal within 6 months postoperatively in 61 cases (63.5%). Compared with the JOC group, the indirect bilirubin (IBIL) level was higher and the albumin level was lower in the JC group before operation (both P<0.05). The result of Kaplan-Meier survival curve analysis showed that the native liver survival rates at 3, 6, 12 and 24 months after operation were 92.3%, 70.9%, 57.8% and 55.8%, respectively. The native liver survival rate of the JC group was higher than that of the JOC group (P=0.000). The rate was also higher in the early JC group when compared with the late JC group (P=0.001). Multivariate Cox regression analysis revealed that gender of male [P=0.049, RR=2.163 (95%CI 1.076?4.797)] and jaundice clearance [P=0.001, RR=11.488 (95%CI 2.726?48.415)] were the protective factors of 2-year native liver survival rate.

Conclusion

·Preoperative IBIL and albumin levels may affect jaundice clearance in the children with type Ⅲ biliary atresia after portoenterostomy; gender of male and jaundice clearance are protective factors for 2-year native liver survival in these children.

Key words： type Ⅲ biliary atresia; portoenterostomy (Kasai's operation); jaundice clearance; native liver survival

Cite this article

Geng-feng JI , Zhi-bo ZHANG . Factors related to prognosis of portoenterostomy for type Ⅲ biliary atresia[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(9) : 1142 -1146 . DOI: 10.3969/j.issn.1674-8115.2021.09.002

References

1 Tam PKH, Chung PHY, St Peter SD, et al. Advances in paediatric gastroenterology[J]. Lancet, 2017, 390(10099): 1072-1082.
2 Nizery L, Chardot C, Sissaoui S, et al. Biliary atresia: clinical advances and perspectives[J]. Clin Res Hepatol Gastroenterol, 2016, 40(3): 281-287.
3 Hopkins PC, Yazigi N, Nylund CM. Incidence of biliary atresia and timing of hepatoportoenterostomy in the United States[J]. J Pediatr, 2017, 187: 253-257.
4 Chung PHY, Zheng S, Tam PKH. Biliary atresia: east versus west[J]. Semin Pediatr Surg, 2020, 29(4): 150950.
5 Scottoni F, Davenport M. Biliary atresia: potential for a new decade[J]. Semin Pediatr Surg, 2020, 29(4): 150940.
6 Jimenez-Rivera C, Jolin-Dahel KS, Fortinsky KJ, et al. International incidence and outcomes of biliary atresia[J]. J Pediatr Gastroenterol Nutr, 2013, 56(4): 344-354.
7 Okubo R, Nio M, Sasaki H, et al. Impacts of early Kasai portoenterostomy on short-term and long-term outcomes of biliary atresia[J]. Hepatol Commun, 2021, 5(2): 234-243.
8 Wang J, Xu Y, Chen Z, et al. Liver immune profiling reveals pathogenesis and therapeutics for biliary atresia[J]. Cell, 2020, 183(7): 1867-1883.e26.
9 Liu Y, Peng C, Wang K, et al. The utility of shear wave elastography and serum biomarkers for diagnosing biliary atresia and predicting clinical outcomes[J]. Eur J Pediatr, 2021. DOI: 10.1007/s00431-021-04176-y.
10 Capparelli MA, Ayarzabal VH, Halac ET, et al. Preoperative risk factors for the early failure of the Kasai portoenterostomy in patients with biliary atresia[J]. Pediatr Surg Int, 2021. DOI: 10.1007/s00383-021-04933-y.
11 Chung PHY, Chan EKW, Yeung F, et al. Life long follow up and management strategies of patients living with native livers after Kasai portoenterostomy[J]. Sci Rep, 2021, 11(1): 11207
12 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 9-32.
13 Davenport M. Biliary atresia: clinical aspects[J]. Semin Pediatr Surg, 2012, 21(3): 175-184.
14 Bezerra JA, Wells RG, Mack CL, et al. Biliary atresia: clinical and research challenges for the twenty-first century[J]. Hepatology, 2018, 68(3): 1163-1173.
15 Wong CWY, Chung PHY, Tam PKH, et al. Long-term results and quality of life assessment in biliary atresia patients: a 35-year experience in a tertiary hospital[J]. J Pediatr Gastroenterol Nutr, 2018, 66(4): 570-574.
16 Davenport M, Caponcelli E, Livesey E, et al. Surgical outcome in biliary atresia: etiology affects the influence of age at surgery[J]. Ann Surg, 2008, 247(4): 694-698.
17 Gu YH, Matsui A. Long-term native liver survival in infants with biliary atresia and use of a stool color card: case-control study[J]. Pediatr Int, 2017, 59(11): 1189-1193.
18 Bove KE, Thrasher AD, Anders R, et al. Inflammation, active fibroplasia, and end-stage fibrosis in 172 biliary atresia remnants correlate poorly with age at Kasai portoenterostomy, visceral heterotaxy, and outcome[J]. Am J Surg Pathol, 2018, 42(12): 1625-1635.
19 Hartley JL, Davenport M, Kelly DA. Biliary atresia[J]. Lancet, 2009, 374(9702): 1704-1713.
20 Zani A, Quaglia A, Hadzi? N, et al. Cytomegalovirus-associated biliary atresia: an aetiological and prognostic subgroup[J]. J Pediatr Surg, 2015, 50(10): 1739-1745.
21 Mack CL. The pathogenesis of biliary atresia: evidence for a virus-induced autoimmune disease[J]. Semin Liver Dis, 2007, 27(3): 233-242.
22 Parolini F, Hadzic N, Davenport M. Adjuvant therapy of cytomegalovirus IgM+ve associated biliary atresia: prima facie evidence of effect[J]. J Pediatr Surg, 2019, 54(9): 1941-1945.
23 Wang ZM, Chen YJ, Peng CH, et al. Five-year native liver survival analysis in biliary atresia from a single large Chinese center: the death/liver transplantation hazard change and the importance of rapid early clearance of jaundice[J]. J Pediatr Surg, 2019, 54(8): 1680-1685.
24 Witt M, van Wessel DBE, de Kleine RHJ, et al. Prognosis of biliary atresia after 2-year survival with native liver: a nationwide cohort analysis[J]. J Pediatr Gastroenterol Nutr, 2018, 67(6): 689-694.
Options
Outlines

/

〈 〉